Literature DB >> 14633994

The PTB interacting protein raver1 regulates alpha-tropomyosin alternative splicing.

Natalia Gromak1, Alexis Rideau, Justine Southby, A D J Scadden, Clare Gooding, Stefan Hüttelmaier, Robert H Singer, Christopher W J Smith.   

Abstract

Regulated switching of the mutually exclusive exons 2 and 3 of alpha-tropomyosin (TM) involves repression of exon 3 in smooth muscle cells. Polypyrimidine tract-binding protein (PTB) is necessary but not sufficient for regulation of TM splicing. Raver1 was identified in two-hybrid screens by its interactions with the cytoskeletal proteins actinin and vinculin, and was also found to interact with PTB. Consistent with these interactions raver1 can be localized in either the nucleus or cytoplasm. Here we show that raver1 is able to promote the smooth muscle-specific alternative splicing of TM by enhancing PTB-mediated repression of exon 3. This activity of raver1 is dependent upon characterized PTB-binding regulatory elements and upon a region of raver1 necessary for interaction with PTB. Heterologous recruitment of raver1, or just its C-terminus, induced very high levels of exon 3 skipping, bypassing the usual need for PTB binding sites downstream of exon 3. This suggests a novel mechanism for PTB-mediated splicing repression involving recruitment of raver1 as a potent splicing co-repressor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633994      PMCID: PMC291850          DOI: 10.1093/emboj/cdg609

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  51 in total

Review 1.  Alternative splicing: increasing diversity in the proteomic world.

Authors:  B R Graveley
Journal:  Trends Genet       Date:  2001-02       Impact factor: 11.639

Review 2.  Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology.

Authors:  D L Black
Journal:  Cell       Date:  2000-10-27       Impact factor: 41.582

3.  Multisite RNA binding and release of polypyrimidine tract binding protein during the regulation of c-src neural-specific splicing.

Authors:  M Y Chou; J G Underwood; J Nikolic; M H Luu; D L Black
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

Review 4.  Alternative splicing: combinatorial output from the genome.

Authors:  Gavin C Roberts; Christopher W J Smith
Journal:  Curr Opin Chem Biol       Date:  2002-06       Impact factor: 8.822

Review 5.  Sorting out the complexity of SR protein functions.

Authors:  B R Graveley
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

Review 6.  Alternative pre-mRNA splicing and proteome expansion in metazoans.

Authors:  Tom Maniatis; Bosiljka Tasic
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

7.  Splicing regulation at the second catalytic step by Sex-lethal involves 3' splice site recognition by SPF45.

Authors:  María José Lallena; Kevin J Chalmers; Salud Llamazares; Angus I Lamond; Juan Valcárcel
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

8.  Cooperative assembly of an hnRNP complex induced by a tissue-specific homolog of polypyrimidine tract binding protein.

Authors:  V Markovtsov; J M Nikolic; J A Goldman; C W Turck; M Y Chou; D L Black
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

9.  Region-specific alternative splicing in the nervous system: implications for regulation by the RNA-binding protein NAPOR.

Authors:  Wenqing Zhang; Haiying Liu; Kyoungha Han; Paula J Grabowski
Journal:  RNA       Date:  2002-05       Impact factor: 4.942

10.  A splicing silencer that regulates smooth muscle specific alternative splicing is active in multiple cell types.

Authors:  Natalia Gromak; Christopher W J Smith
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

View more
  55 in total

1.  Apo raver1 structure reveals distinct RRM domain orientations.

Authors:  Erumbi S Rangarajan; Jun Hyuck Lee; Tina Izard
Journal:  Protein Sci       Date:  2011-06-17       Impact factor: 6.725

Review 2.  Vascular smooth muscle phenotypic diversity and function.

Authors:  Steven A Fisher
Journal:  Physiol Genomics       Date:  2010-08-24       Impact factor: 3.107

3.  TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.

Authors:  Jonathan P Ling; Olga Pletnikova; Juan C Troncoso; Philip C Wong
Journal:  Science       Date:  2015-08-07       Impact factor: 47.728

4.  A consensus CaMK IV-responsive RNA sequence mediates regulation of alternative exons in neurons.

Authors:  Jiuyong Xie; Calvin Jan; Peter Stoilov; Jennifer Park; Douglas L Black
Journal:  RNA       Date:  2005-12       Impact factor: 4.942

5.  Characterization of multimeric complexes formed by the human PTB1 protein on RNA.

Authors:  Caroline Clerte; Kathleen B Hall
Journal:  RNA       Date:  2006-01-23       Impact factor: 4.942

6.  STAR family RNA-binding protein ASD-2 regulates developmental switching of mutually exclusive alternative splicing in vivo.

Authors:  Genta Ohno; Masatoshi Hagiwara; Hidehito Kuroyanagi
Journal:  Genes Dev       Date:  2008-01-29       Impact factor: 11.361

7.  Visualizing protein-RNA interactions inside cells by fluorescence resonance energy transfer.

Authors:  Mike Lorenz
Journal:  RNA       Date:  2008-11-25       Impact factor: 4.942

8.  A nonsense exon in the Tpm1 gene is silenced by hnRNP H and F.

Authors:  Joel L Coles; Martina Hallegger; Christopher W J Smith
Journal:  RNA       Date:  2008-11-26       Impact factor: 4.942

9.  A polypyrimidine tract binding protein, pumpkin RBP50, forms the basis of a phloem-mobile ribonucleoprotein complex.

Authors:  Byung-Kook Ham; Jeri L Brandom; Beatriz Xoconostle-Cázares; Vanessa Ringgold; Tony J Lough; William J Lucas
Journal:  Plant Cell       Date:  2009-01-02       Impact factor: 11.277

10.  Post-Translational Modifications in Polypyrimidine Tract Binding Proteins PTBP1 and PTBP2.

Authors:  Jeffrey M Pina; Janice M Reynaga; Anthony A M Truong; Niroshika M Keppetipola
Journal:  Biochemistry       Date:  2018-06-13       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.